Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Revive Biotechnology
AddedFeb 18, 2024
UpdatedJun 18, 2026
Revive Biotechnology

Revive Biotechnology

Angel

Revive Biotech: Innovating nanotech solutions for ocular health, focusing on retinal artery occlusion.

HQ
Champaign, IL, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Revive Biotechnology was founded with the mission to address the significant unmet need of blinding retinal diseases caused by tissue hypoxia. The company focuses on developing innovative nanotechnology solutions to improve oxygen delivery to hypoxic tissues, specifically targeting conditions like central retinal artery occlusion and other ocular ischemic diseases. Their core product involves nano-carriers designed for the immediate and targeted delivery of oxygen, aiming to enhance visual outcomes and improve the quality of life for affected patients.

Notable affiliated individuals include leading experts in ophthalmology and nanotechnology, who contribute to the company's cutting-edge research and development. Revive Biotechnology has garnered attention from prominent investors in the biotech sector, supporting its mission to revolutionize ocular health. Key achievements include significant advancements in their nano-carrier technology and successful preclinical trials, positioning the company as a promising innovator in the field of ophthalmology. The overall impact of Revive Biotechnology lies in its potential to transform treatment paradigms for retinal diseases, offering hope to millions of patients worldwide.

Revive Biotechnology - Quick Facts

When was Revive Biotechnology founded?

Revive Biotechnology was founded in 2018.

Where is Revive Biotechnology's headquarters located?

Revive Biotechnology's headquarters is located in Champaign, IL, US.

When was Revive Biotechnology's last funding round?

Revive Biotechnology's most recent funding round was for $256k (USD) in November 2020.

How much has Revive Biotechnology raised to-date?

As of Nov 24, 2020, Revive Biotechnology has raised a total of $256k (USD).

How many employees does Revive Biotechnology have?

Revive Biotechnology has 2 employees as of Feb 4, 2024.

Revive Biotechnology - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
  • HealthTech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Nanotechnology
  • Therapeutics
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software